CFO Melissa Epperly resigns; President Cam Gallagher named interim CFO

Zentalis Pharmaceuticals, Inc.

Melissa Epperly resigned as CFO, treasurer, principal financial and accounting officer effective April 5, 2024.
President Cam Gallagher appointed interim CFO, treasurer and principal financial officer; VP Finance Vincent Vultaggio named interim principal accounting officer.
Chief Business Officer Kyle Rasbach will oversee Investor Relations on an interim basis.
Company is conducting a search for a new permanent CFO.
Epperly eligible for severance benefits under her amended employment agreement, subject to execution of a release.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Vincent Vultaggio

interim principal accounting officer

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2024-04-05
Filed: April 11, 2024, 7:59 PM ET

the Company’s Vice President, Finance, Vincent Vultaggio, as interim principal accounting officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vincent Vultaggio was appointed as interim principal accounting officer at Zentalis Pharmaceuticals, Inc..

Action: appointed
Role: interim principal accounting officer

Exact text from the filing

the Company’s Vice President, Finance, Vincent Vultaggio, as interim principal accounting officer

View on SEC.gov

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-24-000087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.